Nuvation Bio’s Global Strategy

Pharmaceutical Executive recently spoke with Nuvation Bio’s president, CEO, and founder David Hung. The growing biotech is focused on oncology treatments is building a strong reputation in the space following a string of regulatory wins.

In June of 2025, Nuvation announced FDA’s approval of Ibtrozi, a next-generation oral ROS1 tyrosine kinase inhibitor (TKI), for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). More recently, the biotech announced that UK’s drug regulatory body accepted the marketing application for taletrectinib.¹

During his conversation with Pharmaceutical Executive, Hung discussed the company’s relationship with the market, it’s current pipeline and upcoming goals, along with his approach to leadership and building a team that’s able to produce strong results.

Pharmaceutical Executive: How has Nuvation developed its global strategy?
David Hung: We're still a relatively small company. We are developing and commercializing drugs in the United States. Outside of the US, we have number of partners.

This includes Innovent Biologics in China, Nippon Kayaku in Japan, and we just announced a deal with Eisai to cover Europe and other parts of the world. For our first program, while we're still a relatively small company, we're going to focus our commercial efforts in the United States, where it's a little less expensive than for us to try to do all of commercialization.

It's very expensive and logistically difficult to do that once we're a bigger company. We may consider trying to commercialize our other assets in the rest of the world, but for now we're really focused on the US, and we'll let our partners commercialize the other parts of the world.

Source

1. Can Nuvation Bio Inc (NUVB) Stock Soar 150% From Current Level. Yahoo Finance. July 13, 2026. https://finance.yahoo.com/markets/stocks/articles/nuvation-bio-inc-nuvb-stock-092851856.html